Translating DNA into a battle plan.
A list of mutations is not a treatment plan. We turn your data into action.
Standard testing labs operate on a simple model: they draw blood or tissue, run it through a machine, and send you a 40-page genomic PDF filled with complex jargon, endless tables, and vague probabilities. They drop this heavy document into your lap, leaving you and your already-overworked doctor wondering, "What do we actually do with this?"
Genetic-Driven Blueprint Care is the pinnacle of precision oncology. We do not believe in handing patients raw data and wishing them luck. Whether you bring us a report you already have, or you need us to run a new, ultra-deep molecular sequence, our objective is the same: take the raw genetic information and build a comprehensive, multi-layered clinical war plan — bundled with 3 months of full Blueprint Care to execute it.
From raw data to a strategic war plan.
We don't just tell you what the mutation is. We tell you exactly what drugs, biosimilars, and active trials are accessible in India right now.
- Resistance Mapping: Flag drugs that will not work — before you take them
- Off-Label & Cross-Tumor Approvals: Unlock hidden drug matches
- Biosimilar Mapping: Drastically reduce drug costs
- Synergistic Combinations & Sequencing: Attack from multiple angles
- Clonal Architecture & Pharmacogenomics: Precision dosing
Advanced cancer requires advanced intelligence.
Standard protocols are built for the "average" patient, but your cancer is entirely unique. This pathway is built for families who need the absolute deepest understanding of their disease.
You Already Have a Report
You have spent lakhs on a massive genomic test from another lab but received a confusing report that nobody has fully explained how to act upon.
Standard Treatments Have Failed
Line 1 treatments have stopped working, the cancer is progressing, and you need to uncover entirely new targeted therapies, immunotherapies, or early-phase trials.
Advanced, Rare, or Refractory Cancer
You have been diagnosed with an advanced (Stage 3/4), rare, or heavily refractory cancer and need to know every single biological vulnerability your tumor currently has.
Avoid Toxic, Ineffective Drugs
You want to avoid the severe, toxic side effects of chemotherapy drugs that, biologically, will not work for your specific tumor due to underlying resistance mutations.
Check Immunotherapy Eligibility
You need to definitively know your tumor's MSI or TMB status to see if you are biologically eligible for advanced Immunotherapy options.
Choose your pathway.
We meet you exactly where you are in your genomic journey. Whether you need us to decipher existing data or capture new, cutting-edge data.
Blueprint Decipher
You already have a report. Let us make it actionable. Our computational AI and clinical team will re-read your existing data, strip away the jargon, and classify every mutation against the Indian healthcare reality.
Includes: Complete Decipher Report + 3 Months of Blueprint Care
- AI-powered re-interpretation of your existing genomic PDF
- Mapping to CDSCO-approved drugs and biosimilars in India
- Active trial matching and compassionate access routes
- Plain-language Hindi summary for you and your family
Onkommon Signature Panels
You need the deepest molecular read of your tumor. Our Signature panels provide the ultimate molecular fingerprint — specialized panels tailored to your exact clinical urgency, tissue availability, and cancer type.
Includes: Complete Signature Report + 3 Months of Blueprint Care
- Ultra-deep sequencing up to 523 genes
- MSI, TMB, and comprehensive biomarker analysis
- VUS annotation with advanced AI
- In-person Tumour Board consultation at KCCIRC
The report architecture.
A standard testing lab classifies variants as either "Actionable" or "Benign," lists a few FDA-approved drugs, and stops there. The Onkommon Intelligence Engine goes significantly deeper.
Therapies with Resistance
We use your genetics to identify drugs that will not work before you even take them. For example, if your tumor carries a specific TP53 mutation resistant to platinum-based chemotherapy, we flag it immediately — so you do not suffer toxicities of a drug that has no chance of curing you.
Prevent toxic mistakesOff-Label & Cross-Tumor Approvals
If you have Thyroid cancer but your tumor carries a PTEN mutation commonly targeted in Breast cancer, standard reports might miss it. We map out the exact clinical evidence to justify using that targeted therapy off-label for your unique case.
Unlock hidden doorsBiosimilar Mapping
We automatically map expensive international branded drugs to CDSCO-approved biosimilars available in India. You receive the exact same clinical efficacy at a fraction of the cost.
Radical cost reductionSynergistic Combinations
Cancer is adaptable. We identify how pairing specific targeted therapies can attack the tumor from multiple angles simultaneously — helping overcome resistance mechanisms before they can fully form.
Multi-pronged attackSequencing Considerations
We outline exactly what order your treating doctor should use the available drugs — when to use targeted oral therapies first, and precisely when to hold back on Immunotherapies until they are biologically necessary.
Play the right cards, in orderClonal Architecture & Dominance
We map the "Clonal Architecture" of your tumor to distinguish between the primary driver (the trunk) and secondary mutations (the branches). This ensures your oncologist strikes at the root cause.
Target the trunk, not the branchesPharmacogenomics Overlay
We analyze how your liver and enzymes will metabolize recommended therapies — helping your doctor adjust dosages perfectly. Prevents severe toxic reactions if you metabolize too slowly, or treatment failure if you metabolize too quickly.
Precision dosing · Metabolism profilingAdvanced computational infrastructure.
Behind every single Onkommon report is an incredibly powerful, enterprise-grade computational backbone designed to find actionable answers where standard platforms simply fail.
AI-Powered VUS Annotation
Many mutations are returned with a frustrating "VUS" label — Variant of Uncertain Significance. We refuse to accept that ambiguity. Our Automatic Learning Platform and machine learning algorithms deeply analyze these findings to identify hidden oncogenic targets that standard labs entirely miss.
Advanced Genomic Interpretation
We transform raw genomic data into highly actionable clinical insights. By continuously comparing your tumor's data against global libraries, published literature, and ongoing trial outcomes, we pinpoint exact oncogenic drivers and link them to specific biomarkers of drug response.
Real-Time Cohort Statistics
Our platform generates real-time visualizations and comprehensive statistics from vast patient and genomic data — including our specialized KCCIRC Northeast India variant cohort. We prevent misclassification of variants common in Indian populations.
International vMTB + In-Person KCCIRC Tumour Board
Some cancers require a global perspective combined with flawless local execution. Our hybrid system is unmatched: we securely share your molecular data with an international panel of world-class oncology experts, then sit with you in person at KCCIRC to translate that global strategy into an actionable roadmap for India.
Not just a machine.
Your data is far too important to be left entirely to an automated algorithm. While AI powers our speed, human expertise ensures our safety. Every report goes through a rigorous 4-step validation process.
AI & ML Interpretation
Our advanced computational models scan millions of data points, global trial registries, and literature databases to find initial drug matches and deeply annotate VUS findings.
Computational Precision Oncologist Review
A highly trained human precision oncology expert meticulously reviews the AI's findings — manually verifying synergistic combinations, resistance flags, and cross-referencing against the latest medical literature.
Medical Oncologist Sign-Off
Before any report is released, the final clinical strategy must be reviewed and officially signed off by an empanelled Medical Oncologist — guaranteeing clinical safety, viability, and relevance for a treating physician.
Plain Hindi/Regional Summary
You do not just receive an intimidating 8-12 page technical English report. We automatically include a clear, 2-page plain-language summary in Hindi (or your requested regional language) so you and your family understand exactly what the science means for your life.
The 3-month Blueprint Care bundle.
Intelligence without execution is just theory. Every Genetic-Driven pathway comes automatically bundled with 3 months of our premium Blueprint Care service — including everything from our standard monthly subscription.
Dedicated Coordinator
Named Clinical Coordinator with weekly check-ins via phone or WhatsApp, plus up to two in-person meetings per month at KCCIRC clinics.
Financial Shield
We take on the grueling administrative paperwork for PAPs and pharmaceutical charity schemes — fighting to radically lower your out-of-pocket costs.
Active Trial Matching
If your genomic report identifies you as a match for an active clinical trial, we actively coordinate with investigators and your doctor to push for immediate enrollment.
Full Logistics & Toxicity Tracking
We manage hospital appointments, brief family caregivers, track day-to-day side effects, and cross-reference medications to prevent dangerous interactions.
How it works.
Five steps from data to execution. We handle the science — you focus on healing.
Pathway & Payment
Select Decipher or a Signature Panel. Complete payment via our secure online portal.
Upload or Draw
Upload your existing PDF report, or our team coordinates your blood draw from home or works with your hospital to acquire tissue.
AI & vMTB
Our 4-step validation and vMTB platform activate — building resistance mapping, off-label recommendations, and sourcing trial matches with international experts.
In-Person KCCIRC Board
Attend your included 1-on-1 Tumour Board meeting at KCCIRC (Delhi or Sikkim). We explain global findings in plain language and hand over your comprehensive report.
3 Months of Care
Your bundled Blueprint Care subscription activates immediately — PAP filings, trial contacts, weekly check-ins, and full logistics support.
Frequently Asked Questions
Everything you need to know about Genetic-Driven Care.
Absolutely not. If your current report is recent and comprehensive, you are the perfect candidate for our Blueprint Decipher pathway. We will take your existing PDF report, run it through our advanced intelligence engine, and map the findings directly to the Indian healthcare reality. We believe in maximizing the data you already have and never push unnecessary re-testing.
Our vMTB (Virtual Molecular Tumour Board) allows our team to consult securely with international experts on your specific molecular data. Following this global review, you are entitled to one in-person session at KCCIRC in Delhi or Sikkim. During this face-to-face meeting, our local clinical experts will sit with you, explain the international board's findings, and plan your precise next steps for treatment in India.
Yes. There are no compromises. The 3 months of Blueprint Care bundled with your genetic pathway includes the exact same weekly check-ins, PAP financial management, trial hunting, and in-person meeting options as our standalone monthly subscription.
A VUS stands for "Variant of Uncertain Significance." It means standard testing labs cannot tell if the mutation is harmful or benign, so they ignore it. We refuse to ignore data. We use our Automatic Learning Platform and machine learning to deeply annotate these findings against massive databases, often discovering that a VUS is actually a highly targetable mutation that standard labs simply missed.
Many targeted therapies and immunotherapies are incredibly expensive, branded biologic drugs. A "biosimilar" is a highly similar, clinically equivalent version of that drug made by a different manufacturer, often available at a significantly lower cost. Our reports automatically map the expensive branded drugs to CDSCO-approved biosimilars available right here in India, drastically reducing your financial burden without sacrificing efficacy.
No. Your Onkommon Care Coordinator is an expert clinical strategist and logistical navigator. They will arm your current treating medical oncologist with this incredibly detailed, evidence-based war plan. Your treating oncologist remains the licensed physician who officially prescribes the medication and oversees your medical care.